RxDoctor Payments DataLook up a doctor →

Zahid Hamid, MD

Internal Medicine · Las Vegas, NVNPI 1972526978

Payments from drug & device makers

$14,967in general payments, 2019–2025

Across 455 payments — averaging $32.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardinal Health 110 LLC$4K
  • AstraZeneca$2K
  • Abbott$1K
  • Amgen$830
  • Novo Nordisk$696
  • Mannkind Corporation$540
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$4,40029%
  • Food & beverage$10,50070%
  • Education$670%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,967 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$218,785
Medicare patients
228
Services billed
2,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide81$85,740
OzempicSemaglutide50$59,590
JardianceEmpagliflozin58$55,945
EliquisApixaban54$50,662
FarxigaDapagliflozin Propanediol45$41,361
XareltoRivaroxaban15$17,972
VascepaIcosapent Ethyl18$10,612
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$10,492
LinzessLinaclotide15$9,903
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,625
JanuviaSitagliptin Phosphate24$8,763
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,787
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,399
Albuterol Sulfate HfaAlbuterol Sulfate49$2,614
Rosuvastatin Calcium149$2,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$261$85,74081 claims
Novo NordiskOzempic$696$59,59050 claims
Boehringer IngelheimJardiance$237$55,94558 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,675$50,98658 claims
PfizerEliquis$157$50,66254 claims
Johnson & JohnsonXarelto$38$17,97215 claims
AbbVieLinzess, Synthroid$464$11,40027 claims
MerckJanuvia$486$8,76324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →